An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
Study of Glecaprevir/Pibrentasvir in Pediatric Subjects with Chronic Hepatitis C Virus (HCV) Infection
Sponsor: AbbVie, Inc.
Enrolling: Male and Female Patients
Study Length: 160 Weeks
Clinic Visits: 13
IRB Number: AAAR2252
U.S. Govt. ID: NCT03067129
Contact: Danilo Gamino: 212-305-6758 / dg3031@cumc.columbia.edu
Additional Study Information: Open-labeled hepatitis C pediatric treatment trial with a two drug direct acting viral oral combination (already approved in adults) across all genotypes for naive or treatment experienced subjects.
This study is closed
Investigator
Steven Lobritto, MD
Do You Qualify?
Has your child been diagnosed with Hepatitis C virus? Yes No
Has your child tested positive for Hepatitis B? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Danilo Gamino
dg3031@cumc.columbia.edu
212-305-6758
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE